S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

AC Immune Stock Forecast, Price & News

-0.25 (-4.87%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
314,247 shs
Average Volume
1.05 million shs
Market Capitalization
$354.55 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

AC Immune logo

About AC Immune

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.


AC Immune SA (NASDAQ:ACIU) Sees Significant Decline in Short Interest
November 29, 2021 |  americanbankingnews.com
AC Immune SA (NASDAQ:ACIU) Short Interest Up 15.9% in October
November 22, 2021 |  americanbankingnews.com
AC Immune (NASDAQ:ACIU) Rating Reiterated by SVB Leerink
November 12, 2021 |  americanbankingnews.com
AC Immune (NASDAQ:ACIU) Sees Strong Trading Volume
November 10, 2021 |  americanbankingnews.com
AC Immune (NASDAQ:ACIU) Announces Earnings Results
November 9, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$16.46 million
Book Value
$3.20 per share


Net Income
$-66.04 million
Pretax Margin




Free Float
Market Cap
$354.55 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.68 out of 5 stars

Medical Sector

962nd out of 1,392 stocks

Pharmaceutical Preparations Industry

451st out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

Is AC Immune a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AC Immune stock.
View analyst ratings for AC Immune
or view top-rated stocks.

How has AC Immune's stock price been impacted by Coronavirus (COVID-19)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACIU shares have decreased by 11.1% and is now trading at $4.88.
View which stocks have been most impacted by COVID-19

Are investors shorting AC Immune?

AC Immune saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 608,900 shares, a decline of 50.9% from the October 31st total of 1,240,000 shares. Based on an average trading volume of 2,190,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.9% of the company's shares are short sold.
View AC Immune's Short Interest

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for AC Immune

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.03.
View AC Immune's earnings history

What price target have analysts set for ACIU?

2 equities research analysts have issued 12-month target prices for AC Immune's shares. Their forecasts range from $16.00 to $17.00. On average, they anticipate AC Immune's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 238.1% from the stock's current price.
View analysts' price targets for AC Immune
or view top-rated stocks among Wall Street analysts.

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Andrea Pfeifer, Chief Executive Officer & Director
  • Jörg Hornstein, Chief Financial Officer
  • Piergiorgio Donati, Chief Technical Operations Officer
  • Marie Kosco-Vilbois, Chief Scientific Officer
  • Johannes Rolf Streffer, Chief Medical Officer

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune CEO Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among AC Immune's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (9.55%), Platinum Investment Management Ltd. (1.46%), Suvretta Capital Management LLC (1.33%), EcoR1 Capital LLC (1.03%), Balyasny Asset Management LLC (1.01%) and Balyasny Asset Management LLC (1.01%).

Which major investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BVF Inc. IL, Point72 Asset Management L.P., Two Sigma Investments LP, BlackRock Inc., Millennium Management LLC, Saturna Capital CORP, and Banque Cantonale Vaudoise.

Which major investors are buying AC Immune stock?

ACIU stock was bought by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Platinum Investment Management Ltd., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Morgan Stanley, Eversept Partners LP, Bellevue Group AG, and Sphera Funds Management LTD..

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $4.88.

How much money does AC Immune make?

AC Immune has a market capitalization of $354.55 million and generates $16.46 million in revenue each year. The company earns $-66.04 million in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does AC Immune have?

AC Immune employs 137 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is www.acimmune.com.

Where are AC Immune's headquarters?

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at (121) 693-9121, via email at [email protected], or via fax at 41-21-345-9120.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.